Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study

被引:3
|
作者
Zhang, Weihe [1 ]
Jiao, Yujuan [2 ]
Cui, Lei [2 ]
Zhang, Yeqiong [2 ]
Jiao, Jinsong [2 ]
Jin, Ming [3 ]
Yuan, Wei [3 ]
You, Yang [4 ]
Wang, Renbin [2 ]
Peng, Dantao [1 ]
机构
[1] China Japan Friendship Hosp, Dept Neurol, 2 Yinghua, Beijing 100029, Peoples R China
[2] China Japan Friendship Hosp, Dept Neurol, Beijing, Peoples R China
[3] China Japan Friendship Hosp, Dept Ophthalmol, Beijing, Peoples R China
[4] 964 Hosp Peoples Liberat Army, Dept Neurol, Changchun, Peoples R China
关键词
efficacy; elderly; neuromyelitis optica spectrum disorder; plasma exchange; safety; PLASMA-EXCHANGE; DIAGNOSTIC-CRITERIA; OUTCOMES; MARKER; ATTACK; AGE;
D O I
10.1177/17562864231162420
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background:Neuromyelitis optica spectrum disorder (NMOSD) is a devastating autoimmune disorder with cycles of escalating relapse. Rates of diagnosis in the elderly are increasing. Therapeutic decision-making is more challenging in elderly patients due to multiple comorbidities and high risk of drug-induced side effects. Objective:This retrospective study assessed the efficacy and safety of standard plasma exchange (PLEX) treatment in an elderly population with NMOSD. Design:Seventy-six patients with NMOSD who received PLEX were apportioned to two groups as either elderly (> 60 years, n = 26) or young (<60 years) at the time of the first procedure. Methods:Therapeutic response was judged according to functional recovery at 6 months, as reflected by Expanded Disability Status Scale (EDSS) and visual outcome scale (VOS) scores. Results:The mean age of the 26 elderly patients was 67.7 +/- 7.9 years (range 60-87 years); the population was predominantly female (88.5%). PLEX sessions were generally well tolerated among the elderly. Compared with the young patients, the elderly had significantly more comorbidities and concomitant medications. Twenty-four (96.0%) elderly patients showed functional improvement at 6 months after PLEX, of which 15 (60.0%) experienced moderate-to-marked improvement. Six months after the initial PLEX treatment, the patients overall experienced a significant improvement in EDSS and VOS scores. Logistic regression showed that severe optic neuritis attack was a significant independent prognostic factor associated with poor PLEX response. The groups were comparable regarding overall or serious adverse events. The rate of transient hypotension was significantly higher in the elderly compared with the young. Conclusion:PLEX is an effective and safe therapy for elderly patients with NMOSD and should be considered a treatment option during NMOSD attacks. In the elderly, preventive measures against hypotension are recommended before PLEX.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Pregnancy-Related Attack in Neuromyelitis Optica Spectrum Disorder With AQP4-IgG: A Single-Center Study and Meta-Analysis
    Deng, Shuwen
    Lei, Qiang
    Lu, Wei
    FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [42] Efficacy and safety of satralizumab from two phase 3 trials in neuromyelitis optica spectrum disorder
    Haskova, Zdenka
    Frishberg, Benjamin
    de Seze, Jerome
    Weinshenker, Brian
    Terada, Yusuke
    Kawata, Yuichi
    Gianella-Borradori, Athos
    von Budingen, Christian
    Klingelschmitt, Gaelle
    Traboulsee, Anthony
    Yamamura, Takashi
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [43] The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey
    Uzunkopru, Cihat
    Tutuncu, Melih
    Gunduz, Tuncay
    Gumus, Haluk
    Sen, Sedat
    Demir, Serkan
    Cinar, Bilge Piri
    Ture, Hatice Sabiha
    Uygunoglu, Ugur
    Togrol, Rifat Erdem
    Terzi, Murat
    Kurtuncu, Murat
    Ozakbas, Serkan
    Tutuncu, Mesude
    Beckmann, Yesim
    Siva, Aksel
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (07)
  • [44] Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder
    Zhang, Chengyi
    Liu, Rui
    Gao, Bin
    Li, Ting
    Wang, Huabing
    Song, Tian
    Ma, Yuetao
    Xu, Wangshu
    Liu, Yun
    Zhang, Xinghu
    Tian, De-Cai
    Yang, Chunsheng
    Shi, Kaibin
    JOURNAL OF NEUROIMMUNOLOGY, 2024, 387
  • [45] Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder
    Huang, Wenjuan
    Wang, Liang
    Xia, Junhui
    Li, Wenyu
    Wang, Min
    Yu, Jian
    Li, Qinying
    Wang, Bei
    Pan, Juyuan
    Du, Lei
    Ma, Jianhua
    Tan, Hongmei
    Chang, Xuechun
    Lu, Chuanzhen
    Zhao, Chongbo
    Lu, Jiahong
    Zhou, Lei
    ZhangBao, Jingzi
    Quan, Chao
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (08) : 2343 - 2354
  • [46] Efficacy and safety of leadless ventricular pacemaker: a single-center retrospective observational study
    Yan, Lin
    Ling, Lin
    Song, Yumeng
    Jiang, Tingbo
    CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2024, 14 (05) : 878 - 889
  • [47] Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study
    Levy, Michael
    Berthele, Achim
    Kim, Ho Jin
    Fujihara, Kazuo
    Nakashima, Ichiro
    Oreja-Guevara, Celia
    Palace, Jacqueline
    Pittock, Sean
    Terzi, Murat
    Totolyan, Natalia
    Viswanathan, Shanthi
    Wang, Kai-Chen
    Pace, Amy
    Yountz, Marcus
    Lawson, Diane
    Meyer, Eva-Laudon
    Wingerchuk, Dean
    NEUROLOGY, 2020, 94 (15)
  • [48] Efficacy of Eculizumab in Acute Phase of Neuromyelitis Optica Spectrum Disorder: A Case Series Study
    Watanabe, Mitsuru
    Masaki, Katsuhisa
    Matsushita, Takuya
    Isobe, Noriko
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (09) : NP12 - NP12
  • [49] Efficacy and safety of rituximab in treating patients with Neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis
    Mirmosayyeb, Omid
    Shaygannejad, Vahid
    Barzegar, Mahdi
    Nehzat, Nasim
    Ghajarzadeh, Mahsa
    AUTOIMMUNITY REVIEWS, 2021, 20 (02)
  • [50] Safety and efficacy of peripheral metaraminol infusion in patients with neurological conditions: a single-center retrospective observational study
    Han, Pan
    Zhou, Yu
    FRONTIERS IN NEUROLOGY, 2024, 15